Mirnext

Mirnext

Year of investment: 2012

Mirnext focuses on the discovery, validation and commercialization of microRNAs as novel biomarkers for cardiovascular disease. The company develops clinically actionable multi-marker tests to improve diagnostic routine and prognostic clinical management of heart failure.